COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.750 -0.010 (-0.21%)

Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 Next >

Is ATAI Stock A Buy After The IPO?

June 16, 2021

ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock.

Via Talk Markets

Here's How This Psychedelic Drug CEO Sees The Industry Evolving

June 09, 2021

Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said.

Via Investor's Business Daily

What Do You Really Know About Psychedelics And Psychedelics Stocks?

June 08, 2021

According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That...

Via Benzinga

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

June 08, 2021

Via FinancialNewsMedia

Topics Law Enforcement

Exposures Legal

Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York

June 07, 2021

Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ...

Via Benzinga

Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price

June 02, 2021

Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at...

Via Talk Markets

Meet PsyBio, A Company Producing Psilocybin From Genetically-Modified Bacteria

May 28, 2021

As psychedelics draw closer to legalization, companies in the industry have yet to figure out the most efficient and cost-effective way of producin...

Via Benzinga

Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week

May 27, 2021

Welcome to the Cannabis...

Via Benzinga

Topics Cannabis

Exposures Cannabis

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week

May 27, 2021

Welcome to the Cannabis...

Via Benzinga

Topics Cannabis

Exposures Cannabis

How Risky Are Psychedelic Stocks?

May 26, 2021

Public and private companies are studying the use of psilocybin ("magic mushrooms") to treat severe depression, and MDMA (ecstasy) to treat post-traumatic stress disorder.

Via The Motley Fool

Topics Cannabis

Exposures Cannabis

Is Compass Pathways a Buy?

May 25, 2021

The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic mushrooms." Will this be a money-maker?

Via The Motley Fool

Topics Cannabis Law Enforcement

Exposures Cannabis Legal

Can Psychedelics Actually Cure Depression and PTSD?

May 25, 2021

There is now data suggesting that magic mushrooms and ecstasy -- combined with talk therapy -- may help people with severe depression and post-traumatic stress disorder.

Via The Motley Fool

Topics Cannabis

Exposures Cannabis

Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen

May 20, 2021

MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline.

Via Investor's Business Daily

Compass Pathways Offers Chance on Exploratory Mental Health Treatments

May 18, 2021

Over the past year, CMPS stock has been going nowhere fast. However, there's been recent progress in advancing psilocybin-assisted therapy.

Via InvestorPlace

Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public

May 17, 2021

Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa...

Via Benzinga

Exposures Product Safety

Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts

May 14, 2021

Compass Pathways (NASDAQ:CMPS), a company researching psyc...

Via Benzinga

COMPASS Pathways plc (CMPS) Q1 2021 Earnings Call Transcript

May 13, 2021

CMPS earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Exposures Financial

Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing

May 13, 2021

Via FinancialNewsMedia

Exposures Product Safety

Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week

May 11, 2021

Welcome to the Cannabis Countdo...

Via Benzinga

Topics Cannabis

Exposures Cannabis

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021

May 11, 2021

Upgrades For CEVA Inc (NASDAQ:CEVA), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, CEVA had an EPS of $0.01, compared to year...

Via Benzinga

Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders

May 05, 2021

Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable.

Via Talk Markets

The Next Psychedelic Stock To Uplist On The Nasdaq?

May 04, 2021

As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next?

Via Talk Markets

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

May 04, 2021

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week

Via Benzinga

Topics Cannabis

Exposures Cannabis

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

April 28, 2021

Via FinancialNewsMedia

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

April 28, 2021

Gainers Akari Therapeutics (NASDAQ:AKTX) stock moved upwards by 14.1% to $2.67 during Wednesday's pre-market session. The company's market cap stands at $102.7...

Via Benzinga

Second-Chance Buying Opportunity With Psychedelic Stock Warrants

April 27, 2021

Psychedelic stock warrants delivered epic returns for investors in the big rally in these stocks in 2020. After the pullback in 2021, some of these warrants are again looking attractive.

Via Talk Markets

MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To Mainstream

April 27, 2021

MindMed stock rose in its Nasdaq listing debut on Tuesday, making it the latest psychedelic drug developer to land on a major U.S. exchange.

Via Investor's Business Daily

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

April 27, 2021

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week

Via Benzinga

Topics Cannabis

Exposures Cannabis

Majority Of Pure-Play Psychedelic Drug Stocks Went Up Last Week

April 26, 2021

41 psychedelic drug stocks trade on the various North American stock exchanges and in the past week 24 went up, 12 went down and 5 had no change in price.

Via Talk Markets

Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading

April 26, 2021

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ...

Via Benzinga

< Previous 1 2

...

22 23 24 25 26 27 28 29 Next >

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.